638 related articles for article (PubMed ID: 17242282)
1. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
[TBL] [Abstract][Full Text] [Related]
2. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice.
Potì F; Gualtieri F; Sacchi S; Weißen-Plenz G; Varga G; Brodde M; Weber C; Simoni M; Nofer JR
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1505-12. PubMed ID: 23640484
[TBL] [Abstract][Full Text] [Related]
3. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice.
Keul P; Tölle M; Lucke S; von Wnuck Lipinski K; Heusch G; Schuchardt M; van der Giet M; Levkau B
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):607-13. PubMed ID: 17158351
[TBL] [Abstract][Full Text] [Related]
4. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.
Klingenberg R; Nofer JR; Rudling M; Bea F; Blessing E; Preusch M; Grone HJ; Katus HA; Hansson GK; Dengler TJ
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2392-9. PubMed ID: 17761943
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds.
Tölle M; Levkau B; Kleuser B; van der Giet M
Eur J Clin Invest; 2007 Mar; 37(3):171-9. PubMed ID: 17359484
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
8. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C
J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis.
Keul P; Lucke S; von Wnuck Lipinski K; Bode C; Gräler M; Heusch G; Levkau B
Circ Res; 2011 Feb; 108(3):314-23. PubMed ID: 21164103
[TBL] [Abstract][Full Text] [Related]
10. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
11. FTY720 modulates human oligodendrocyte progenitor process extension and survival.
Miron VE; Jung CG; Kim HJ; Kennedy TE; Soliven B; Antel JP
Ann Neurol; 2008 Jan; 63(1):61-71. PubMed ID: 17918267
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.
Walter DH; Rochwalsky U; Reinhold J; Seeger F; Aicher A; Urbich C; Spyridopoulos I; Chun J; Brinkmann V; Keul P; Levkau B; Zeiher AM; Dimmeler S; Haendeler J
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):275-82. PubMed ID: 17158356
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
14. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.
Wolf AM; Eller K; Zeiser R; Dürr C; Gerlach UV; Sixt M; Markut L; Gastl G; Rosenkranz AR; Wolf D
J Immunol; 2009 Sep; 183(6):3751-60. PubMed ID: 19692647
[TBL] [Abstract][Full Text] [Related]
15. Topical treatment targeting sphingosine-1-phosphate and sphingosine lyase abrogates experimental allergic rhinitis in a murine model.
Kleinjan A; van Nimwegen M; Leman K; Hoogsteden HC; Lambrecht BN
Allergy; 2013 Feb; 68(2):204-12. PubMed ID: 23253209
[TBL] [Abstract][Full Text] [Related]
16. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.
Deguchi Y; Andoh A; Yagi Y; Bamba S; Inatomi O; Tsujikawa T; Fujiyama Y
Oncol Rep; 2006 Oct; 16(4):699-703. PubMed ID: 16969482
[TBL] [Abstract][Full Text] [Related]
17. FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis.
Zhang ZY; Zhang Z; Schluesener HJ
Neuropathol Appl Neurobiol; 2009 Oct; 35(5):487-95. PubMed ID: 19207263
[TBL] [Abstract][Full Text] [Related]
18. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
19. Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor(-/-) mice.
Lau PP; Li L; Merched AJ; Zhang AL; Ko KW; Chan L
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):143-9. PubMed ID: 16254210
[TBL] [Abstract][Full Text] [Related]
20. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
